AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026, as part of a drive to raise its revenues to $80 billion by the end
Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part
Generic drugmaker Accord Healthcare has announced a £50 million ($65 million) investment in the UK that will include the construction of a new medicines manufacturing facility.
Damage to a Baxter manufacturing facility caused by Hurricane Helene, which rolled across the east US a couple of weeks ago, has led to shortages in some critical medicines.